FDA Approves Tudriqev With Nivolumab for Advanced Melanoma Treatment After Anti-PD-1 Therapy Failure

The U.S. Food and Drug Administration (FDA) has granted accelerated approval for Tudriqev (vusolimogene oderparepvec-wtpg), formerly known as RP1, in combination with nivolumab for adults with unresectable advanced cutaneous melanoma whose disease has progressed following treatment with an anti-PD-1 antibody-based regimen.

The approval represents a significant development in melanoma treatment, particularly for patients who have limited options after immune checkpoint inhibitor therapy. Tudriqev is designed to activate the immune system against cancer cells through a targeted oncolytic immunotherapy approach.

The approval was announced by Replimune Group, Inc., a biotechnology company focused on developing next-generation cancer immunotherapies. The FDA approval is based on clinical data demonstrating objective response rates and duration of response in patients with advanced melanoma.

A New Treatment Option for Patients With Advanced Melanoma

Melanoma is one of the most aggressive forms of skin cancer. While immune checkpoint inhibitors such as anti-PD-1 therapies have improved outcomes for many patients, a significant number of individuals either do not respond or eventually experience disease progression.

Advanced melanoma occurs when cancer spreads beyond the original tumor site to other areas of the body. For patients whose melanoma progresses after anti-PD-1 therapy, treatment options remain limited and the prognosis can be challenging.

Tudriqev combined with nivolumab aims to provide a new therapeutic approach by combining direct tumor destruction with immune system activation. The therapy is intended for patients who need additional treatment options after previous immunotherapy has stopped working.

Results From the IGNYTE Clinical Trial

The FDA approval was supported by results from the IGNYTE clinical trial, a Phase 1/2 study evaluating Tudriqev alone and in combination with nivolumab in adults with advanced solid tumors, including melanoma.

In the melanoma patient group evaluated for efficacy, 91 patients who had at least one non-injected lesion were included. These patients received Tudriqev combined with nivolumab after confirmed progression following anti-PD-1-based treatment.

The study showed:

• Objective response rate of 24.2%
• Median duration of response of 14.1 months
• Activity across patients with advanced disease and different clinical characteristics

The patient population included individuals with Stage 4 melanoma, previous anti-PD-1 treatment, PD-L1 negative tumors, and cancer involving organs such as the lungs and liver.

The results suggest that Tudriqev may provide meaningful clinical benefit for patients who previously had limited treatment choices.

How Tudriqev Works

Tudriqev is a genetically modified herpes simplex virus type 1 (HSV-1) oncolytic viral therapy. Unlike traditional antiviral uses of herpes viruses, Tudriqev has been engineered to selectively target and attack tumor cells.

After injection into tumors, Tudriqev is designed to:

• Replicate within cancer cells
• Cause tumor cell destruction
• Release tumor antigens
• Stimulate immune system activity
• Encourage immune cells to recognize and attack cancer

The therapy includes genetic modifications intended to improve cancer cell killing and immune activation. Tudriqev also produces GM-CSF, a molecule designed to support immune cell activation and maturation.

When combined with nivolumab, a PD-1 immune checkpoint inhibitor, the treatment aims to enhance the body's ability to mount an anti-cancer immune response.

Administration and Treatment Approach

Tudriqev is administered through direct injection into tumors. It can be delivered into superficial tumors as well as deeper or visceral lesions with the assistance of imaging technology.

The recommended dose is determined based on tumor size. Healthcare providers evaluate patients individually to determine the appropriate treatment approach.

Because Tudriqev is a live viral therapy, specific precautions are required to reduce the risk of accidental exposure.

Safety Profile and Side Effects

In clinical studies, Tudriqev combined with nivolumab was generally well tolerated. Most treatment-related side effects were mild to moderate in severity.

Common adverse reactions reported in patients included:

• Fatigue
• Fever
• Chills
• Nausea
• Diarrhea
• Vomiting
• Constipation
• Decreased appetite
• Injection site reactions
• Headache
• Cough
• Shortness of breath
• Rash
• Itching
• Muscle and joint pain

Serious adverse reactions occurred in some patients, and healthcare providers should monitor patients for possible complications, including immune-related effects, infections, and signs of visceral injury.

Patients and caregivers should avoid direct contact with injected tumors, dressings, or bodily fluids following treatment. Any accidental exposure should be cleaned appropriately.

Importance of Confirmatory Clinical Trials

The FDA granted this approval under the accelerated approval pathway. This means approval was based on clinical measures such as objective response rate and duration of response that are expected to predict patient benefit.

Continued approval may depend on successful verification of clinical benefit through additional confirmatory studies.

Replimune is currently conducting the Phase 3 IGNYTE-3 trial to further evaluate Tudriqev combined with nivolumab.

Replimune’s Role in Cancer Immunotherapy Development

Replimune Group, Inc. is developing a platform of oncolytic immunotherapies designed to stimulate immune responses against cancer.

The company’s RPx platform uses engineered HSV-1 viruses intended to selectively destroy tumors while activating immune responses. Researchers believe this approach may have potential across multiple cancer types and in combination with other therapies.

The approval of Tudriqev represents a major milestone for the company and the broader field of oncolytic immunotherapy.

What This Approval Means for Melanoma Patients

For patients with advanced melanoma who have progressed after anti-PD-1 treatment, new therapeutic options are urgently needed. The approval of Tudriqev with nivolumab provides another potential approach for managing difficult-to-treat disease.

While additional research is ongoing, the therapy represents continued progress toward personalized and immune-based cancer treatments.

Source

Source: Replimune Group, Inc. FDA announcement regarding accelerated approval of Tudriqev. Additional clinical information: IGNYTE clinical trial data published in the Journal of Clinical Oncology.

Disclaimer

This article is for informational and educational purposes only and does not constitute medical advice. FDA approvals, treatment decisions, and cancer care plans should always be discussed with a qualified healthcare professional. Patients should consult their oncologist or medical provider regarding whether Tudriqev, nivolumab, or any other treatment option may be appropriate for their individual condition. Treatment outcomes and risks may vary between patients.